MTOR and renal cell carcinoma: Furthermore, data for the efficacy of other targeted therapies used in RCC, such as tyrosine kinase inhibitors (TKIs) and inhibitors of mammalian target of rapamycin (mTOR), are limited and must be extrapolated from trials of clear cell histology patients (14, 15).